{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:19:27Z","timestamp":1786987167774,"version":"build-2736575974"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2021YFF0702003"],"award-info":[{"award-number":["2021YFF0702003"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computers in Biology and Medicine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.compbiomed.2024.108040","type":"journal-article","created":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T08:03:22Z","timestamp":1706429002000},"page":"108040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Integrating network pharmacology and drug side-effect data to explore mechanism of liver injury-induced by tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"170","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1054-9463","authenticated-orcid":false,"given":"Miaomiao","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanxuan E.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.compbiomed.2024.108040_bib1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer","volume":"17","author":"Du","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.compbiomed.2024.108040_bib2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.compbiomed.2024.108040_bib3","series-title":"Tyrosine Kinase Inhibitors","author":"Thomson","year":"2023"},{"key":"10.1016\/j.compbiomed.2024.108040_bib4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","article-title":"Tyrosine kinase inhibitors: multi-targeted or single-targeted?","volume":"2","author":"Broekman","year":"2011","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1080\/03602532.2022.2149775","article-title":"Metabolic activation of tyrosine kinase inhibitors: recent advance and further clin-ical practice","volume":"55","author":"Yan","year":"2023","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.compbiomed.2024.108040_bib6","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s12272-011-1108-x","article-title":"Assessment of reactive metabolites in drug-induced liver injury","volume":"34","author":"Lee","year":"2011","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.compbiomed.2024.108040_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108256","article-title":"Recent advances in metabolism and toxicity of tyrosine kinase inhibitors","volume":"237","author":"Zhao","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.compbiomed.2024.108040_bib8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2012.09.004","article-title":"Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a me-ta-analysis","volume":"39","author":"Teo","year":"2013","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.compbiomed.2024.108040_bib9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.clgc.2012.09.005","article-title":"Fatal liver failure in a patient treated with sunitinib for renal cell carcin-oma","volume":"11","author":"Mermershtain","year":"2013","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.compbiomed.2024.108040_bib10","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027731","article-title":"Pazopanib-induced severe acute liver injury: a case report","volume":"100","author":"Choi","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.compbiomed.2024.108040_bib11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41571-021-00597-8","article-title":"Harnessing big data to characterize immune-related adverse events","volume":"19","author":"Jing","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib12","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","article-title":"Multi-omics prediction of immune-related adverse events during checkpoint im-munotherapy","volume":"11","author":"Jing","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.compbiomed.2024.108040_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003779","article-title":"Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy","volume":"10","author":"Jing","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.compbiomed.2024.108040_bib14","article-title":"GLP-1 receptor agonist-associated tumor adverse events: a real-world study fro-m 2004 to 2021 based on FAERS","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib15","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2021.20503","article-title":"Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic d-isorders in the WHO pharmacovigilance database VigiBaseTM from 2010 to 2020","volume":"151","author":"Ortland","year":"2021","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.compbiomed.2024.108040_bib16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41581-023-00705-0","article-title":"Network medicine: an approach to complex kidney disease phenotypes","volume":"19","author":"Pandey","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib17","doi-asserted-by":"crossref","first-page":"15235","DOI":"10.1021\/acs.est.0c03998","article-title":"Probing the mechanism of hepatotoxicity of hexabromocyclododecanes through toxicological network analysis","volume":"54","author":"Dai","year":"2020","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tips.2021.11.004","article-title":"Network pharmacology: curing causal mechanisms instead of treating sympt-oms","volume":"43","author":"Nogales","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.compbiomed.2024.108040_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","article-title":"Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf."},{"key":"10.1016\/j.compbiomed.2024.108040_bib21","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/jcpt.13404","article-title":"Anaplastic lymphoma kinase tyrosine kinase inhibitor-induced hepatic failure in lung cancer patients: a study of signal mining and analysis of the FDA adverse event reporting system database","volume":"46","author":"Zhou","year":"2021","journal-title":"J. Clin. Pharm. Therapeut."},{"key":"10.1016\/j.compbiomed.2024.108040_bib22","unstructured":"FAERS, FDA Adverse Event Reporting System, https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers, 2022 (accessed March 2022)."},{"key":"10.1016\/j.compbiomed.2024.108040_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/science.1257601","article-title":"Uncovering disease-disease relationships through the incomplete interactome","volume":"347","author":"Menche","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.compbiomed.2024.108040_bib24","article-title":"Identification of potential therapeutic targets and mechanisms of COVID-19 through network analysis and screening of chemicals and herbal ingredients","volume":"23","author":"Wang","year":"2022","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.compbiomed.2024.108040_bib25","doi-asserted-by":"crossref","first-page":"W216","DOI":"10.1093\/nar\/gkac194","article-title":"DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)","volume":"50","author":"Sherman","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.compbiomed.2024.108040_bib26","doi-asserted-by":"crossref","first-page":"D991","DOI":"10.1093\/nar\/gks1193","article-title":"NCBI GEO: archive for functional genomics data sets--update","volume":"41","author":"Barrett","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.compbiomed.2024.108040_bib27","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with D-ESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071963","article-title":"Pharmaceutical strategies to improve druggability of potential drug candid-ates in nonalcoholic fatty liver disease therapy","volume":"15","author":"Amatya","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.compbiomed.2024.108040_bib29","article-title":"Retinoids in health and disease: a role for hepatic stellate cells in affecting retinoid levels","volume":"1865","author":"Haaker","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.compbiomed.2024.108040_bib30","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1073\/pnas.1322731111","article-title":"Loss of liver E-cadherin induces sclerosing cholangitis and promotes carci-nogenesis","volume":"111","author":"Nakagawa","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.compbiomed.2024.108040_bib31","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1161\/CIRCULATIONAHA.113.001225","article-title":"Depressing mitochondria-reticulum interactions protects cardiomyocytes fro-m lethal hypoxia-reoxygenation injury","volume":"128","author":"Paillard","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.compbiomed.2024.108040_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/nu10010029","article-title":"Disturbed vitamin A metabolism in non-alcoholic fatty liver disease (NAF-LD)","volume":"10","author":"Saeed","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.compbiomed.2024.108040_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105218","article-title":"Endoplasmic reticulum stress and protein degradation in chronic liver disease","volume":"161","author":"Xia","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.compbiomed.2024.108040_bib34","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41419-022-05282-x","article-title":"HSF2BP protects against acute liver injury by regulating HSF2\/HSP70\/MAPK sign-aling in mice","volume":"13","author":"Bi","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.compbiomed.2024.108040_bib35","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jhep.2018.01.003","article-title":"Hsp 72 protects against liver injury via attenuation of hepatocellular death, ox-idative stress, and JNK signaling","volume":"68","author":"Levada","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchromb.2018.05.005","article-title":"Development and validation of an analytical method for regorafenib and its metab-olites in mouse plasma","volume":"1090","author":"Fu","year":"2018","journal-title":"J. Chromatogr. B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.compbiomed.2024.108040_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.955263","article-title":"A high throughput method for Monitoring of Sorafenib, regorafenib, cabozanti-nib and their metabolites with UPLC-MS\/MS in rat plasma","volume":"13","author":"Gu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00894-019-4125-1","article-title":"Theoretical study on the mechanism of N- and alpha-carbon oxidation of lapat-inib catalyzed by cytochrome P450 monooxygenase","volume":"25","author":"Huang","year":"2019","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.compbiomed.2024.108040_bib39","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1124\/mol.110.065839","article-title":"Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib","volume":"78","author":"Teng","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13045-020-01026-6","article-title":"The management of metastatic GIST: current standard and investigational therapeutics","volume":"14","author":"Kelly","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib41","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1111\/bph.14664","article-title":"Impaired clearance of sunitinib leads to metabolic disorders and hepatotoxicity","volume":"176","author":"Zhao","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205747","article-title":"Altered hepatic genes related to retinol metabolism and plasma retinol in pat-ients with non-alcoholic fatty liver disease","volume":"13","author":"Pettinelli","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.compbiomed.2024.108040_bib43","article-title":"PPARA\/RXRA signalling regulates the fate of hepatic non-esterified fatty acids in a sheep model of maternal undernutrition","volume":"1865","author":"Xue","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.compbiomed.2024.108040_bib44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bcpt.13246","article-title":"Functional characterization of 27 CYP3A4 protein variants to metabolize regora-fenib in vitro","volume":"125","author":"Li","year":"2019","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib45","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/liv.13217","article-title":"Regorafenib induced severe toxic hepatitis: characterization and discussion","volume":"36","author":"Sacre","year":"2016","journal-title":"Liver Int."},{"key":"10.1016\/j.compbiomed.2024.108040_bib46","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/dmd.119.088823","article-title":"Interindividual variation in CYP3A activity influences lapatinib bioactiva-tion","volume":"47","author":"Bissada","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.compbiomed.2024.108040_bib47","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1021\/acs.chemrestox.1c00426","article-title":"Interindividual variability in cytochrome P450 3A and 1A activity influ-ences sunitinib metabolism and bioactivation","volume":"35","author":"Burnham","year":"2022","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib48","first-page":"443","article-title":"Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma","volume":"71","author":"Keisner","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.compbiomed.2024.108040_bib49","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3389\/fphar.2017.00367","article-title":"Hepatocellular toxicity associated with tyrosine kinase inhibitors: mitochond-rial damage and inhibition of glycolysis","volume":"8","author":"Paech","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib50","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jat.3551","article-title":"Mechanisms of toxicity associated with six tyrosine kinase inhibitors in hum-an hepatocyte cell lines","volume":"38","author":"Mingard","year":"2018","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib51","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10565-021-09689-8","article-title":"The endoplasmic reticulum participated in drug metabolic toxicity","volume":"38","author":"Huang","year":"2022","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib52","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1124\/dmd.120.000296","article-title":"Aldehyde oxidase contributes to all-trans-retinoic acid biosynthesis in hu-man liver","volume":"49","author":"Zhong","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.compbiomed.2024.108040_bib53","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jhep.2018.06.008","article-title":"Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoh-olic fatty liver disease","volume":"69","author":"Lebeaupin","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib54","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.1039\/D1QM00630D","article-title":"HSPA1A-siRNA nucleated gold nanorods for stimulated photothermal therapy through strategic heat shock to HSP70","volume":"5","author":"Kim","year":"2021","journal-title":"Mater. Chem. Front."},{"key":"10.1016\/j.compbiomed.2024.108040_bib55","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/13813455.2017.1369548","article-title":"Supplementation of all trans retinoic acid ameliorates ethanol-induced endopla-smic reticulum stress","volume":"124","author":"Nair","year":"2018","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.compbiomed.2024.108040_bib56","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acs.chemrestox.8b00005","article-title":"Cytochromes P450 1A2 and 3A4 catalyze the metabolic activation of sun-itinib","volume":"31","author":"Amaya","year":"2018","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.compbiomed.2024.108040_bib57","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/00498254.2018.1489167","article-title":"A metabolomic perspective of pazopanib-induced acute hepatotoxicity in mic-e","volume":"49","author":"Wang","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1016\/j.compbiomed.2024.108040_bib58","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1002\/med.21577","article-title":"Identifying the reactive metabolites of tyrosine kinase inhibitors in a co-mprehensive approach: implications for drug-drug interactions and hepatotoxicity","volume":"39","author":"Paludetto","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.compbiomed.2024.108040_bib59","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/toxsci\/kfaa026","article-title":"Quantitative transcriptional biomarkers of xenobiotic receptor A-ctivation in rat liver for the early assessment of drug safety liabilities","volume":"175","author":"Podtelezhnikov","year":"2020","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.compbiomed.2024.108040_bib62","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/gutjnl-2018-316906","article-title":"Tight junction proteins in gastrointestinal and liver disease","volume":"68","author":"Zeisel","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.compbiomed.2024.108040_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20020298","article-title":"Homeostasis of glucose and lipid in non-alcoholic fatty liver disease","volume":"20","author":"Chao","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.compbiomed.2024.108040_bib64","doi-asserted-by":"crossref","first-page":"6408","DOI":"10.1038\/s41467-022-34258-w","article-title":"Hepatic thyroid hormone signalling modulates glucose homeostasis through the r-egulation of GLP-1 production via bile acid-mediated FXR antagonism","volume":"13","author":"Yan","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.compbiomed.2024.108040_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313105","article-title":"TG68, a novel thyroid hormone receptor-beta agonist for the treatment of NAFLD","volume":"22","author":"Caddeo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.compbiomed.2024.108040_bib60","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1053\/j.gastro.2015.02.056","article-title":"Beta-catenin signaling and roles in liver homeostasis, injury, and tumorigenesis","volume":"148","author":"Monga","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.compbiomed.2024.108040_bib61","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.4161\/cc.3.12.1321","article-title":"NF-kappaB and JNK: an intricate affair","volume":"3","author":"Bubici","year":"2004","journal-title":"Cell Cycle"}],"container-title":["Computers in Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482524001240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482524001240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T14:46:16Z","timestamp":1727275576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010482524001240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":65,"alternative-id":["S0010482524001240"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiomed.2024.108040","relation":{},"ISSN":["0010-4825"],"issn-type":[{"value":"0010-4825","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating network pharmacology and drug side-effect data to explore mechanism of liver injury-induced by tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Computers in Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiomed.2024.108040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108040"}}